Trial Profile
A Phase II Study to Assess the Efficacy of the Anti-PD-L1 Antibody Atezolizumab (MPDL3280A) Administered With Stereotactic Ablative Radiotherapy (SABR) in Patients With Metastatic Tumours
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Colorectal cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Renal cell carcinoma; Sarcoma; Soft tissue sarcoma; Tumours
- Focus Therapeutic Use
- Acronyms SABR-PDL1
- 24 Oct 2023 Results (n=60) assessing colorectal (CRC) cohort of the SABR-PDL1 trial that evaluated the PD-L1 inhibitor atezolizumab in combination with stereotactic body radiation therapy (SBRT) in advanced cancer patients, presented at the 48th European Society for Medical Oncology Congress.
- 17 Feb 2020 Planned number of patients changed from 180 to 187.
- 17 Feb 2020 Planned End Date changed from 1 Nov 2020 to 1 Oct 2020.